[Form 4] Omada Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Omada Health insider sale: The Form 4 shows Wei-Li Shao, President and officer of Omada Health, sold 2,407 shares of common stock on 09/05/2025 at a price of $24.28 per share. After the sale, Shao beneficially owned 76,540 shares, reported as direct ownership. The filing was signed by an attorney-in-fact on 09/09/2025.

Positive

• None.

Negative

• Insider disposition: President Wei-Li Shao sold 2,407 shares, reducing direct holdings to 76,540 shares.
• No explanatory details: The Form 4 contains no statement about the reason for the sale or any 10b5-1 plan.

Insights

Securities Analyst

TL;DR: Officer sold a modest number of shares, reducing direct holdings to 76,540 shares; transaction appears routine.

The reported sale of 2,407 shares at $24.28 is a specific, non-derivative disposition by the company's President. As recorded, the transaction changes the officer's direct share count but does not indicate any derivative activity or changes to compensation arrangements. There is no additional context in the filing about purpose or any related plans.

Corporate Governance Expert

TL;DR: Filing discloses an ordinary insider sale with no accompanying explanatory disclosure; procedural compliance is satisfied.

The Form 4 meets Section 16 disclosure requirements by reporting the disposition, price, and resulting beneficial ownership. The document does not show involvement in Rule 10b5-1 plans or any amendment. From a governance perspective, the sale is documented but not clearly material on its own given the size relative to total reported holdings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shao Wei-Li

(Last) (First) (Middle)

C/O OMADA HEALTH, INC.

611 GATEWAY BLVD, SUITE 120

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Omada Health, Inc. [ OMDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/05/2025		F		2,407	D	$24.28	76,540	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Nathan Salha, as Attorney-in-Fact for Wei-Li Shao	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Omada Health insider Wei-Li Shao report on Form 4 (OMDA)?

The filing reports a sale of 2,407 shares of common stock on 09/05/2025 at $24.28 per share, leaving 76,540 shares beneficially owned.

How many shares does Wei-Li Shao own after the reported transaction?

After the reported sale, Wei-Li Shao beneficially owned 76,540 shares, reported as direct ownership.

Was the sale part of a 10b5-1 trading plan according to the Form 4?

No. The Form 4 does not indicate the transaction was made under a Rule 10b5-1 trading plan.

When was the Form 4 signed and by whom?

The signature block shows the filing was signed by Nathan Salha as attorney-in-fact for Wei-Li Shao on 09/09/2025.